Cathepsin H (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Pro-cathepsin H (CTSH, UniProt P09668) expressed in HEK293 cells. Suited for lysosomal protease activity assays, inhibitor IC50 determinations, and antibody validation as a defined positive control.
Expression system
HEK293
Cat. #
REC-CathepsinH

In stock

SKU
REC-CathepsinH
$498.00

Target Overview

Cathepsin H (gene: CTSH; UniProt P09668) is a lysosomal cysteine protease of the papain superfamily encoded by a 335-amino-acid precursor, pro-cathepsin H. Unlike the strictly endopeptidase-active cathepsins, Cathepsin H exhibits both aminopeptidase and endopeptidase activities, a dual catalytic character that distinguishes it within the cathepsin family and underpins its broad role in intracellular protein degradation. This recombinant is produced in HEK293 mammalian cells, providing the post-translational processing — including N-linked glycosylation and correct disulfide formation — characteristic of the native lysosomal enzyme. Mammalian-cell expression is particularly relevant for Cathepsin H because proper glycosylation influences trafficking to the lysosomal compartment and contributes to the stability of the mature enzyme under assay conditions. Researchers use this reagent in several in-vitro contexts. In enzymatic activity assays, the recombinant serves as a defined source of active enzyme for substrate cleavage measurements using fluorogenic peptide substrates. In inhibitor screening campaigns, it provides a consistent, lot-characterised enzyme for IC50 determinations against small-molecule or peptidic inhibitor series. As a structurally defined protein standard, it is well suited for surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding studies characterising inhibitor or interactor affinities. For researchers performing antibody validation, this recombinant can be used as a positive control antigen alongside the matched Triple Point Biologics Cathepsin H antibody (SKU: RP-CathepsinH), validated for Western blot against human samples, with predicted reactivity to non-human primates.

Background

Cathepsin H (CTSH) is a ubiquitously expressed lysosomal cysteine protease that contributes to the bulk degradation of proteins within the endo-lysosomal system. Its unique combination of aminopeptidase and endopeptidase activities, described in detail by Wang et al. (2023, Biochem Pharmacol), sets it apart from most other cathepsins and raises ongoing questions about which of its activities predominates in specific cellular contexts and disease states. That review consolidates current knowledge of its molecular mechanism, substrate preferences, and structural features — making it a useful reference for researchers designing activity or substrate-specificity assays with this recombinant. In oncology research, CTSH has been investigated in several tumour types. A candidate pathway analysis by Luyapan et al. (2023, Hum Mol Genet) identified CTSH as a gene influencing lung cancer risk through the surfactant protein pathway, implicating lysosomal protease activity in pulmonary epithelial biology. In clear cell renal cell carcinoma, CTSH methylation status was included in a five-gene signature associated with overall survival outcomes in patient cohorts (Jing et al., 2021, J Clin Lab Anal), pointing to CTSH expression regulation as a feature of the tumour epigenome and motivating in-vitro studies of its enzymatic activity in renal cancer cell models. Neurological research has also highlighted CTSH as a locus of interest. Li et al. (2023, Neuropsychopharmacology) used functional genomics to characterise a protective CTSH locus identified in Alzheimer's disease genome-wide association studies, providing mechanistic evidence that CTSH influences microglial gene regulation relevant to neuroinflammation — a finding that positions this recombinant as useful for cell-free mechanistic assays in that research context. Separately, a Mendelian randomisation study (Dong et al., 2024, BMC Psychiatry) examined genetically predicted cathepsin levels in relation to bipolar disorder, further illustrating the breadth of neuropsychiatric research in which CTSH is being studied as a circulating or CNS-relevant protease. Across these fields, the availability of a well-characterised, mammalian-expressed recombinant Cathepsin H supports experiments ranging from basic enzymology to target validation — without relying on native-tissue preparations that carry batch variability and biosafety considerations. Researchers pairing this recombinant with the matched Triple Point Biologics antibody (RP-CathepsinH) gain a directly matched antigen–antibody set for Western blot and IHC controls, produced under consistent lot-release criteria built on three decades of proteinase-reagent manufacturing.

Applications

  • Fluorogenic peptide substrate cleavage assay to measure aminopeptidase and endopeptidase activity of recombinant Cathepsin H
  • Inhibitor IC50 determination against small-molecule or peptidic cysteine protease inhibitor series
  • Positive control antigen in Western blot validation of anti-Cathepsin H antibodies (pairs with SKU RP-CathepsinH)
  • IHC assay optimisation: recombinant protein spiked into cell lysate or tissue section controls
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding kinetics for inhibitor or interactor characterisation
  • Substrate identification and cleavage-site mapping by mass spectrometry-based degradomics
  • Enzyme titration and specific-activity lot-release testing for standardisation across multi-site studies

References

  1. Wang Y et al. Cathepsin H: Molecular characteristics and clues to function and mechanism. Biochem Pharmacol. 2023. doi:10.1016/j.bcp.2023.115585. PMID: 37148981.
  2. Li Y et al. Functional genomics identify causal variant underlying the protective CTSH locus for Alzheimer's disease. Neuropsychopharmacology. 2023. doi:10.1038/s41386-023-01542-2. PMID: 36739351.
  3. Luyapan J et al. Candidate pathway analysis of surfactant proteins identifies CTSH and SFTA2 that influences lung cancer risk. Hum Mol Genet. 2023. doi:10.1093/hmg/ddad095. PMID: 37471639.
  4. Dong C et al. Mendelian randomisation analysis to explore the association between cathepsins and bipolar disorder. BMC Psychiatry. 2024. doi:10.1186/s12888-024-06210-3. PMID: 39482620.
  5. Jing X et al. A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma. J Clin Lab Anal. 2021. doi:10.1002/jcla.24031. PMID: 34716619.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight band should I expect for recombinant Cathepsin H on SDS-PAGE or Western blot?

The 335-amino-acid CTSH precursor has a theoretical MW of ~37 kDa, but the HEK293-expressed recombinant runs at approximately 28–30 kDa under reducing SDS-PAGE conditions, reflecting removal of the signal peptide and propeptide to yield the mature two-chain form, plus N-linked glycosylation. The heavy chain runs near 23–25 kDa and the light chain near 5–6 kDa; under non-reducing conditions these migrate as a single ~28–30 kDa species held by a disulfide bridge. Confirm purity is >90% by the dominant band(s) in that region.

Is this recombinant Cathepsin H the single-chain proenzyme or the mature processed form?

The recombinant is the mature, active form, not the 37 kDa pro-cathepsin H precursor. HEK293 expression and processing yield the disulfide-linked heavy-chain/light-chain heterodimer characteristic of the lysosomal enzyme. Because the propeptide is removed, the product is active upon thawing without an additional activation step — unlike some bacterially expressed zymogens that require exogenous processing. If your experiment specifically requires pro-cathepsin H, this product is not appropriate for that application.

What substrates are recommended for a Cathepsin H aminopeptidase activity assay in vitro?

For aminopeptidase activity, Arg-AMC (H-Arg-7-amido-4-methylcoumarin) is the standard fluorogenic substrate, generating a highly sensitive AMC signal (Ex 360 nm / Em 460 nm). Because Cathepsin H retains endopeptidase activity, Z-Phe-Arg-AMC is also widely used to monitor total cysteine protease activity, though it is less selective. A working substrate concentration of 25–100 µM in 50 mM sodium acetate pH 5.5, 2 mM DTT, 1 mM EDTA is a practical starting point for initial Vmax and inhibitor screening experiments.

What assay buffer conditions should I use to maximize recombinant Cathepsin H activity?

Cathepsin H has a pH optimum in the range of 5.0–6.5, consistent with its lysosomal function. A standard activity buffer of 50 mM sodium acetate pH 5.5, 2 mM DTT, and 1 mM EDTA reliably activates the enzyme before assay — pre-incubate the protein in this buffer for 10–15 minutes at 37°C. Avoid prolonged exposure above pH 7.0, which accelerates inactivation. Note the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) keeps the enzyme stable but is not the assay buffer; dilute accordingly just before use.

What starting concentration of recombinant Cathepsin H should I use for IC50 inhibitor assays?

A starting concentration of 1–5 nM active enzyme is typical for IC50 determination with fluorogenic substrates like Arg-AMC at 50 µM. Confirm your specific lot's activity (units/mg) from the certificate of analysis, then titrate down to the lowest concentration giving a robust signal-to-background ratio (≥5:1) in the linear phase of the reaction. Using the minimum active enzyme concentration minimizes tight-binding inhibitor artifacts and keeps substrate depletion below 10% during the kinetic window — a common source of IC50 overestimation with cysteine proteases.

Can I use recombinant Cathepsin H as a Western blot positive control with the matched TPB antibody RP-CathepsinH?

Yes — this is one of the primary intended cross-uses. REC-CathepsinH and RP-CathepsinH are developed and validated together in-house, so the antibody is confirmed to recognize the same recombinant on Western blot. Load 25–50 ng of REC-CathepsinH per lane alongside your cell lysate samples; expect the antibody to detect the mature ~28–30 kDa band (and potentially a faint ~37 kDa pro-form in cell lysates). This pairing also serves as a reliable antibody validation control, useful if you are working under reproducibility guidelines or preparing a publication methods section.

How much recombinant Cathepsin H should I load for Western blot when validating the RP-CathepsinH antibody?

For a clean positive control lane, 25–50 ng per lane on a standard 12% SDS-PAGE gel is sufficient for detection with RP-CathepsinH at the recommended 1:1,000–1:2,000 primary antibody dilution and an HRP-conjugated secondary. If using enhanced ECL, 10–25 ng may be adequate. Start at 50 ng to establish signal, then optimize downward. Running a two-fold dilution series (50, 25, 12.5 ng) on a single gel is an efficient way to confirm linearity and set your baseline before comparing against endogenous lysate expression levels.

How should I store and handle recombinant Cathepsin H to preserve enzymatic activity over time?

Upon receipt, centrifuge briefly and store at -20°C in the supplied single-use aliquots. The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — maintains stability for at least 12 months under these conditions. Avoid repeated freeze-thaw cycles; each cycle measurably reduces specific activity in cysteine proteases. On the day of the experiment, thaw one aliquot on ice, dilute into your assay buffer immediately before use, and discard any remainder rather than refreezing. Carrier protein (0.1% BSA) may be added if working at sub-nanomolar concentrations to reduce surface adsorption losses.

Validation imagery coming soon

Western blot validation figures for REC-CathepsinH will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →